Melkior Resources Inc. (MKRIF)

Verve Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022	Aug 31, 2021	Aug 31, 2020
Net Income	-0.21	-0.01	-0.15	-0.33	0.02	-0.64
Loss (Gain) From Sale of Investments	-	-	0.22	-0.04	-0.74	-0
Stock-Based Compensation	0.07	-	-	0.14	0.52	0.41
Other Operating Activities	-0.15	-0.15	-0.32	-0.05	-0.18	-0.03
Change in Accounts Payable	0.04	-0.03	0	0.03	-0.07	0.02
Change in Other Net Operating Assets	-0.01	0.01	-0.02	-0.02	0.01	0.01
Operating Cash Flow	-0.26	-0.19	-0.26	-0.27	-0.44	-0.22
Capital Expenditures	-0.83	-0.69	-1.37	-0.31	-0.77	-0.65
Investment in Securities	-	-	0.03	-	0.87	0.15
Other Investing Activities	0	0.17	0.05	0.14	0.03	0.22
Investing Cash Flow	-0.82	-0.51	-1.29	-0.17	0.14	-0.28
Issuance of Common Stock	0.21	0.47	1.43	0.84	1.81	-
Other Financing Activities	-	-0.03	-0.06	-0	-	-
Financing Cash Flow	0.21	0.44	1.38	0.84	1.81	-
Net Cash Flow	-0.88	-0.26	-0.18	0.4	1.51	-0.5
Free Cash Flow	-1.09	-0.87	-1.64	-0.57	-1.2	-0.87
Free Cash Flow Per Share	-0.03	-0.03	-0.06	-0.03	-0.06	-0.04
Levered Free Cash Flow	-1.09	-0.96	-1.63	-0.11	-0.31	-1.07
Unlevered Free Cash Flow	-1.09	-0.96	-1.63	-0.11	-0.31	-1.07
Change in Net Working Capital	0.08	0.14	0.07	-0.3	-0.46	0.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.